Radiotherapy Induces Development of Fragmented QRS in Patients with Breast Cancer

Adar, Adem; Canyılmaz, Emine; Kırış, Abdülkadir; İlter, Abdulselam; Serdar, Lasif; Memis, Yahyahan; Bahat, Zümrüt; Özer, Orhan

doi:10.1159/000431030

Cited by 12 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 Presently, surgical therapy and radiotherapy and chemotherapy were the major therapeutic strategies. 4 Dismally, some of patients having undergone surgical therapy still were died of postoperative metastasis, 5 the side-effects caused by radiotherapy were continuous, 6 , 7 drug resistance remained to be a several challenge. 8 , 9 These outcomes was probably attributed to poor understanding of BC pathogenesis or mechanism of drug action.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer

Ni¹,

Peng²,

Yang³

et al. 2018

OTT

View full text Add to dashboard Cite

IntroductionThe aim of this study was to evaluate the expression of C-type lectin domain family 3 member A (CLEC3A) and its clinical significance in breast invasive ductal cancer (IDC) as well as its effect on breast cancer (BC) cell proliferation and metastasis. In this study, the level of CLEC3A expression in The Cancer Genome Atlas (TCGA) datasets was analyzed.Materials and methodsClinical collected samples and BC cells were measured using quantitative reverse transcription polymerase chain reaction. Its correlations with patients’ clinicopathological characteristics were analyzed by Pearson’s chi-squared test. Overall survival (OS) analysis was performed by the Kaplan–Meier method and Cox’s proportional-hazards model. BC cell proliferation, migration, and invasion by CLEC3A knockdown were assessed using Cell Counting Kit-8 and colony formation assay, wound healing model and transwell assay, respectively, in BT474 cell line. Activities of survival factors and phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) signaling were measured by testing key molecules using Western blot assay.ResultsCLEC3A expression was markedly higher in breast IDC tissues than normal breast tissues or adjacent normal tissue. Patients with high CLEC3A expression related to higher lymph node and poorer OS of breast IDC. CLEC3A knockdown by siRNA could inhibit the BC cells BT474 proliferation, migration, and invasion, together with a decrease in expression of key proteins in survival factors and PI3K/AKT signaling pathway.ConclusionElevated CLEC3A expression may correlate with breast IDC metastatic potential and indicated a poor prognosis in breast IDC. CLEC3A knockdown inhibited BC cell growth and metastasis might be through suppressing PI3K/AKT signaling activity. These findings unravel that CLEC3A is a promising therapeutic target for BC in the future.

show abstract

Section: Introductionmentioning

confidence: 99%

Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer

Ni¹,

Peng²,

Yang³

et al. 2018

OTT

View full text Add to dashboard Cite

show abstract

“…Moreover, an inferior outcome and higher risk of recurrences were more common for other organ sites, including the breast, than gastric and thyroid EMZL among those who underwent RT (14)(15)(16). Part of the answer may be that breast radiation can cause a broad spectrum of complications including lung injury, myocardial fibrosis, and secondary malignancies (18)(19)(20). These results indicate that RT, though a suitable option for localized diseases, is met with skepticism for treating early-stage PBMZL.…”

Section: Discussionmentioning

confidence: 99%

Conventional Treatments Cannot Improve Outcomes of Early-Stage Primary Breast Marginal Zone Lymphoma

et al. 2021

View full text Add to dashboard Cite

IntroductionPrimary breast marginal zone lymphoma (PBMZL) is a rare occurrence and less is known about its characteristics, treatments, and outcomes.MethodsWe retrospectively reviewed 370 cases of early-stage PBMZL from the Surveillance, Epidemiology, and End Results database. Statistical analyses were performed to describe clinical features, determine prognostic factors, and compare different therapeutic strategies.ResultsAt a median follow-up of 68.5 months, the 5-year overall survival (OS) and disease-specific survival (DSS) rate were 81.2 and 95.4%, respectively. We divided the cohort into four treatment groups and compared their characteristics and survival: radiotherapy (RT) ± surgery (Sx) (n = 142, 38.4%), Sx alone (n = 71, 19.2%), any chemotherapy (CT) (n = 63, 17.0%), and none of the above (n = 94, 25.4%). Age of onset and laterality of lesions tended to relate to the choice of different treatments. Multivariate Cox analysis showed that advanced age (>60 years), concomitant tumor, and any CT (vs RT ± Sx) predicted poorer OS, while for DSS, there was no meaningful indicator (P > 0.05). Patients aged >60 years or treated with any CT seemed to have shorter DSS, but the difference only approached statistical significance. Then we applied a propensity score-matched analysis to demonstrate that neither RT- nor Sx-containing therapy could bring a better OS or DSS. The competing risk model suggested that CT was the only contributor to higher PBMZL-specific mortality.ConclusionOur results show an indolent behavior of early-stage PBMZL with long-term survival. Conventional oncological treatments fail to bring survival benefits; especially CT is detrimental to survival, suggesting that observation may be advisable in the management of early-stage PBMZL, and further research on novel targeted agents is warranted for patients in need.

show abstract

“…26.6% (67/252) of breast cancer patients had fQRS after anthracycline-based chemotherapy [ 16 ]. At 1-year follow-up, 19 of 52 (37.4%) breast cancer patients receiving locoregional radiotherapy had developed fQRS on ECG [ 17 ]. Moreover, the prevalence of fQRS significantly increased in large B-cell lymphoma patients treated with anthracycline-based chemotherapy (15.8% to 28.9%, P =0.041) [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

Electrocardiographic Characteristics of Breast Cancer Patients Treated with Chemotherapy

Liang

Wang

Yin

et al. 2020

Cardiology Research and Practice

View full text Add to dashboard Cite

Introduction. Patients receiving chemotherapy for breast cancer may be at risk of developing cardiac dysfunction and electrophysiological abnormalities. The aim of this study is to evaluate alterations in electrocardiographic (ECG) parameters in breast cancer patients receiving chemotherapy. Materials and Methods. This was a prospective single-center cohort study conducted in the Fourth Hospital of Hebei Medical University, China. Participants with breast cancer referred for chemotherapy from May 1, 2019, to October 1, 2019, were invited to participate in the study. Standard 12-lead ECG and echocardiography were performed at baseline or before chemotherapy (prechemotherapy) (T0), after 1 cycle (T1), after 3 cycles (T2), and at the end of chemotherapy (T3). Results. A total of 64 patients with diagnosed breast cancer undergoing chemotherapy were included. Echocardiographic parameters showed no significant variation during the entire procedure (all P > 0.05 ). The incidence of abnormal ECG increased from 43.75% at baseline to 65.63% at the end of chemotherapy, of which only the prevalence of fragmented QRS (fQRS) was significantly increased after the drug regimen (26.56% to 53.13%). At the end of the treatment, heart rate, P-wave dispersion, corrected QT interval, T-peak to T-end, RR, SV1, RV5, Sokolow–Lyon index (SLI), and index of cardioelectrophysiological balance deteriorated markedly (all P < 0.05 ). The area under the curve for SLI and QT dispersion (QTd) derived by ECG was 0.710 and 0.606, respectively. The cutoff value with 2.12 of SLI by ECG had a sensitivity of 67.2% and specificity of 71.9% for differentiating patients after therapy from baselines. The cutoff value with 0.55 of QTd had a sensitivity of 60.9% and specificity of 60.9%. Conclusions. The current study demonstrated that ECGs can be used to detect electrophysiological abnormalities in breast cancer patients receiving chemotherapy. ECG changes can reflect subclinical cardiac dysfunction before the echocardiographic abnormalities.

show abstract

Radiotherapy Induces Development of Fragmented QRS in Patients with Breast Cancer

Cited by 12 publications

References 23 publications

Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer

Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer

Conventional Treatments Cannot Improve Outcomes of Early-Stage Primary Breast Marginal Zone Lymphoma

Electrocardiographic Characteristics of Breast Cancer Patients Treated with Chemotherapy

Contact Info

Product

Resources

About